Considering human life is always subjective to change, it makes a skill like adaptability the most important part of your arsenal. Humans have understood it well enough throughout the history, hence their tendency of just slipping into any setting remains as impressive as ever. Now, while our proficiency in this regard is unquestionable, we do end up requiring a helping hand at times so to turn the process a lot more seamless. Such a need has guided us towards the construction of some really ingenious concepts, but if we take a moment and assess each one, we’ll see how no concept even come close to matching technology’s prowess. Viewed as a rebellious creation in the early days, technology wasn’t quick to win everyone’s trust. Nevertheless, when it became clear that its unique offerings weren’t a bogus by any means, the world’s stance started to soften a little. This change of heart will continue to get bigger over time, eventually convincing us to put all our chips on the creation. The decision will pay off rather sensationally, and it will do so within different areas across the human spectrum. An area, however, that was a more significant part of the tech revolution than plenty others happened to be our medical sector. Technology’s entry into healthcare was a pivotal moment; because whatever followed would go on to transform the way we used to look at medical discipline. In fact, despite having raised the healthcare floor beyond all expectations, the link-up is still pulling off new wonders every day, and the same is quite evident in a recent partnership.
physIQ, a pioneer in digital medicine, and CellCarta, a global leader in precision medicine services, have officially announced a strategic partnership, which will facilitate a study on personalization of vaccine development procedures. Named VIII (Vaccine-Induced Inflammation Investigation), the study will essentially look to monitor individualized human responses to vaccines. According to certain reports, it will carry out the said task using medical-grade biosensors and blood samples Of course; these mediums don’t have to work all by themselves, as there is also an artificial intelligence platform in the picture. This platform, alongside immunologic biomarkers, will help in making sense of the collected physiological and immune system activation data, therefore paving the way for individualized baselines, and consequentially, more accurate predictions about future immune responses. On a granular level, CellCarta’s technology will handle the measurement of humoral and cellular responses, whereas it is physIQ’s proprietary platform, which is expected to do all the analysis.
“Our goal is to provide tools that help accelerate the therapeutic development of personalized vaccine regimens by looking at the full immune response. This is important because we know there are unique differences in how people react to all vaccines,” said Steven Steinhubl, MD, physIQ chief medical officer and principal investigator for the study. This near real-time capture of patient data potentially allows us to rapidly correlate physiological changes to immune responses and minimize possible adverse reactions early.”
By using biosensors instead of consumer wearables, the two companies are hoping that they are able to unlock meaningful assessments in three key areas i.e. changes in physiologic variables (ECG, skin temperature and their permutations), the vaccine’s holistic impact on the individual’s daily routine, and the core interaction between different variables.
As far as results of the study are concerned, they are slated to be released in the upcoming months.
